Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

al product for the treatment of allergy symptoms

2008 Financial Outlook

-- We expect our net revenue for 2008 will be approximately $75 to $82

million.

-- We expect our gross margin for 2008 will be approximately 70% to 73%,

subject to quarterly fluctuations based on revenue mix.

-- Depending upon the progress of our clinical and pre-clinical programs,

we expect our research and development expenses in 2008 will be

approximately $34 to $38 million, including stock-based compensation

expense, which we estimate will be approximately $1.5 to $2 million.

-- We anticipate our selling, general, and administrative expenses for

2008 will be approximately $50 to $54 million, including stock-based

compensation expense, which we estimate will be approximately $2.5 to

$3.5 million.

Conference Call

ISTA will host a conference call with a simultaneous webcast today, March 6, 2008, at 5:00 PM Eastern Time, to discuss its fourth quarter and full-year 2007 results. To access the live conference call, U.S. and Canadian participants may dial 866-831-6270; international participants may dial 617-213-8858. The access code for the live call is 99457780. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the call is 57762235. This conference call will also be webcast live and archived on ISTA's website for 30 days at http://www.istavision.com.

ABOUT ISTA PHARMACEUTICALS

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... EDISON, N.J. , May 6, 2015 Bone ... $2M funding round with Hankey Capital, LLC ("Hankey Capital") of ... developing a proprietary protein for use in bone regenerative medicine ... Nell-1) for use with patients undergoing spinal fusion. ... "We are pleased with the completion of this round of ...
(Date:5/6/2015)... Follow us on LinkedIn ... with diameter ranging between 2 to 10 nanometers, ... materials market. The unique electroluminescent, photoluminescent, photo-physical, and ... confinement effect render the nanoparticles versatile and flexible ... technological, and commercial applications. A host of value-added ...
(Date:5/6/2015)... -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of ... Cassian Yee , M.D., Professor, Department of Melanoma ... of Texas MD Anderson Cancer Center joined its scientific ... Immunology, Division of Cancer Medicine, and Director, Solid Tumor ... University of Texas MD Anderson Cancer Center.  ...
(Date:5/6/2015)... Dr Jaspreet Singh , Senior Research ... a speech at the 2015 Asian Starch Conference, to be ... Center.  , ... topic: ,Potato Starch: A Potential Source for the Creation ... Co-editor of a 528 page text book entitled "Advances ...
Breaking Biology Technology:Bone Biologics Corp Completes Financing With Hankey Capital, LLC 2Bone Biologics Corp Completes Financing With Hankey Capital, LLC 3Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 2Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 3Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2
... Pharmaceuticals wins the EFQM Excellence Awards 2011, the first ... by EFQM, the award recognizes business performance measured against ... Model. Another 9 organisations received Prizes for role model ... Excellence. 118 independent assessors visited 20 organisations ...
... and IPSWICH, Mass., Oct. 25, 2011 SwitchGear ... services for studying regulatory elements in the human genome, ... Inc. (NEB) to create a new dual reporter assay ... Luciferase Assay System and NEB,s BioLux® Cypridina ...
... Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ... today that its work entitled "Evaluation of the Safety ... Volunteers" will be presented at the Eleventh Annual Meeting ... San Francisco, California. "The selection of Oramed ...
Cached Biology Technology:1 Award Winner and 9 Prize Winners in the EFQM Business Excellence Awards 2SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System 2Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA) 2
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... working on innovative energy supply solutions are included in ... Science Foundation program aimed at promoting environmental sustainability. ... a physics professor, were among the 101 scientists and ... for the Sustainable Chemistry, Engineering and Materials, or SusChEM, ...
... A drug currently used to treat intestinal worms ... which untreated can erode the structuresincluding bonethat hold the ... of print in Antimicrobial Agents and Chemotherapy . ... which is a polymicrobial biofilm, off of the root ...
... OLEDs are already used in the displays of smart phones ... with high contrast, but come with a serious drawback: typically, ... the device is actually converted into light. This ratio can ... platinum or iridium to the active material, but these elements ...
Cached Biology News:NSF awards to UT Arlington researchers will fuel sustainable solutions 2Drug may guard against periodontitis, and related chronic diseases 2Novel LEDs pave the way to cheaper displays 2
Goat polyclonal to Centaurin alpha 2**...
... background ,This solution greatly enhances antigen-antibody reactions, ... obtained with conventional methods. ,Two kinds of ... antibodies, which can suppress the background and ... versatility ,It is applicable to various assay ...
Monocarboxylate (lactate) transporter 2...
Mouse anti human pro-Relaxin-2...
Biology Products: